A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Active, not recruiting
Pfizer
Phase 1
2014-03-25
This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients.
PF-04449913 will be administered orally as a single agent in patients with select advanced
hematologic malignancies, or in combination with LDAC [Low-Dose Ara-C] or cytarabine and
daunorubicin in previously untreated patients with AML [Acute Myeloid Leukemia] or high-risk
MDS [Myelodysplastic Syndrome], or in combination with azacitidine in previously untreated
patients with AML.
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Terminated
Pfizer
Phase 2
2014-10-06
A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated
with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety
and tolerability. Following the lead-in, a phase 2, double blind, 2-arm study, randomized 2:1
to oral single-agent glasdegib versus placebo in 201 patients resistant or intolerant to
ruxolitinib.
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
Active, not recruiting
Pfizer
Phase 1
2015-04-28
This multi center open label Phase 1b study is designed to evaluate the safety, efficacy,
pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined
with azacitidine in patients with previously untreated Higher Risk Myelodysplastic Syndrome
(MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). This clinical
study includes two components: (a) a safety lead in cohort (LIC) and (b) an expansion phase
with an AML cohort and an MDS cohort.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
